Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity

• Published in: Biomedicine & pharmacotherapy Vol. 140; p. 111702
• Main Authors: Monahan, David S., Flaherty, Eimhear, Hameed, Aamir, Duffy, Garry P.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-08-2021; Elsevier
• Subjects: Anthracyclines; Carvedilol; Chemotherapy induced cardiotoxicity; Dexrazoxane; Doxorubicin; Resveratrol; PBS; Anthracyclines; Carvedilol; IC50; ROS; Resveratrol; Dexrazoxane; CCK-8; DCFDA; ATRA; Chemotherapy induced cardiotoxicity; Doxorubicin
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2021.111702

Cancer is one of the leading causes of deaths worldwide with 18.1 million deaths per year. Although there have been significant advances in anti-cancer therapies, they can often result in side effects with cardiovascular complications being the most severe. Dexrazoxane is the only currently approved treatment for prevention of anthracycline induced cardiotoxicity but there are concerns about its use due to the development of secondary malignancies and myelodysplastic syndrome. Additionally, it is only recommended in patients who are due to receive a total cumulative dose of 300 mg/m2 of doxorubicin or 540 mg/m2 of epirubicin. Thus, there exists an urgent need to develop new therapeutic strategies to counteract anthracycline induced cardiotoxicity. The h9c2 cardiomyoblast was investigated for its differentiation capacity and used to screen and compare promising prophylactics for doxorubicin induced cardiotoxicity. The half maximal inhibitory concentration of doxorubicin was determined in differentiated h9c2 cells after 24 h of exposure, to establish a model for drug screening. Cells were treated with dexrazoxane, resveratrol, and carvedilol either 3 h or 24 h prior to doxorubicin treatment. The ability of these cardioprotectants to prevent cardiotoxicity was analysed using the cck-8 cell viability assay and the dichlorofluorescin diacetate (DCFDA) reactive oxygen species (ROS) assay. There was no significant increase in survival in treatment groups after 3 h, however, at 24 h, resveratrol significantly improved survival compared to all other groups (p < 0.05). Additionally, dexrazoxane and resveratrol significantly decreased ROS formation at 3 h (p < 0.05) and all groups significantly decreased ROS production at 24 h (p < 0.001). This work is the first comparison of these cardioprotectants and suggests that resveratrol may be a more effective treatment in the prevention of anthracycline induced cardiotoxicity, compared to dexrazoxane and carvedilol. However, further work will be needed in order to decipher the exact mechanism and potential of this drug in the clinic.
[Display omitted]
•Anthracycline induced cardiotoxicity lead to heart failure with high mortality rate.•Dexrazoxane may cause secondary malignancies and myelodysplastic syndrome.•First comparison of resveratrol, dexrazoxane and carvedilol as a cardioprotectant.•Resveratrol increased h9c2 cell survival and reduced ROS production.•Resveratrol may be more effective in cardiotoxicity prevention.